Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 14, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3/IL-1β Pathway Inhibitor
March 11, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7-Directed Molecular Glue Degrader
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
January 31, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
January 08, 2024 07:15 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2024
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
November 21, 2023 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 09, 2023 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases
November 07, 2023 10:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
October 27, 2023 07:00 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules
October 26, 2023 16:30 ET
|
Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules